Persistent patent ductus arteriosus (PDA) in preterm infants can result in serious hemodynamic changes causing respiratory, gastrointestinal and renal morbidities if not treated within the first week of life. The treatment options available are a conservative approach, pharmacological treatment with cyclo-oxygenase (COX) inhibitors and surgical ligation. The COX inhibitors approved for use in the United States are indomethacin and ibuprofen lysine. Both of these drugs are equally effective in closing the PDA. Subtle differences exist between these two preparations. Indomethacin has a protective effect on the incidence of intraventricular hemorrhage (IVH) but reduces the blood flow to the kidneys and the brain. Ibuprofen is less toxic but has no effect on IVH. Efficacy of pharmacological treatment is influenced by timing of initiation of therapy. Surgical treatment is the only option when pharmacological treatment fails to close the PDA in symptomatic infants. Long-term neurological and respiratory morbidities are associated with surgical ligation. This paper reviews these medical considerations in the treatment options for PDA in premature infants.
Introduction
Patency of the ductus arteriosus is essential for fetal survival. After birth, in term infants, the ductus usually closes within the first day of life, starting with functional closure followed by anatomical closure with vascular remodeling. 1 In preterm infants, the closure is delayed or does not occur. 2 The persistence of the patent ductus arteriosus (PDA) in preterm infants is inversely related to gestational age and birth weight. The incidence of PDA is 70% in preterm infants weighing less than 1000 g and 29 weeks gestational age. 3 Although spontaneous closure of the ductus will occur in approximately 34% of these extremely low-birth-weight (ELBW) infants, failure of the ductus to close in remaining infants can result in potentially life-threatening sequelae. Failure of the PDA to close leads to hemodynamically significant left to right shunting of blood and undesirable pulmonary, renal and gastrointestinal effects, 4, 5 including pulmonary edema and hemorrhage, congestive cardiac failure, intraventricular hemorrhage (IVH), cerebral vascular accidents, necrotizing enterocolitis (NEC), feeding intolerance, poor weight gain, bronchopulmonary dysplasia (BPD) and death. Therefore, diagnosis and appropriate treatment of the PDA is essential to prevent these morbidities.
Diagnosis of PDA PDA usually presents with at least one or more symptoms, including bounding pulses with wide pulse pressure, hyperdynamic precardium, heart murmur, worsening respiratory status, edema and/or oliguria. However, in addition to clinical diagnosis, the echocardiogram remains the gold standard in confirming the presence of hemodynamically significant PDA. The criteria for significant PDA is ductal size of >1.5 mm, LA:AO ratio of >1, leftto-right shunting of blood, end diastolic reversal of blood flow in the aorta and poor cardiac function. 6 The timing of the echocardiogram is also vitally important in making a decision to treat because within the first 24 h of life, about one-third of PDAs will begin to close spontaneously and will not require treatment, and pharmacologic treatment may be more effective when initiated within the first week of life.
Treatment options for PDA
Once the diagnosis is confirmed, the treatment options include conservative medical management, pharmacological therapy or surgical ligation. Conservative medical management involves fluid restriction, watchful waiting and ventilator support. 7 This approach is associated with a high failure rate, especially in low-birth-weight infants. Pharmacological treatment with one of the two available cyclo-oxygenase (COX) inhibitors is effective in 70 to 80% of ELBW infants. 7 Surgical ligation involves thoracotomy and is associated with such significant morbidities as pneumothorax, chylothorax, infection, laryngeal nerve paralysis, respiratory compromise, blood pressure fluctuations, BPD, retinopathy of prematurity and death. [8] [9] [10] Recently, severe neurosensory impairment and cerebral injury have been reported with ductal ligation.
11 Therefore, surgical ligation should be considered as a last option in selected infants with symptomatic PDA who have failed medical treatment. Clearly, pharmacotherapy is the therapy of choice for safe and effective treatment of the hemodynamically significant PDA.
Pharmacotherapy of PDA Pharmacotherapy of PDA involves the use of COX inhibitors, which have been shown to be safe and effective in the majority of treated infants. 7 COX inhibitors block the conversion of arachidonic acid to various prostaglandins 7, 12 that are involved in maintaining the patency of the ductus arteriosus in the fetus. 1 By inhibiting this conversion, COX inhibitors block the production of prostaglandins, thereby allowing the ductus to close. There are two isoforms of COX inhibitors (COX 1 and 2) described. 13 The two available pharmacological agents approved by the Food and Drug Administration (FDA) in the United States are IV indomethacin (Indocin; Ovation Pharmaceuticals, Deerfield, IL, USA) and IV ibuprofen lysine (NeoProfen). These drugs are chemically different and inhibit COX 1 and 2 isoforms to different degrees. 10 Indomethacin has stronger COX 1 inhibition, which has been attributed to undesirable gastrointestinal, cerebral and renal side effects. Ibuprofen lysine has less COX 1 inhibition, resulting in less vasoconstrictive side effects on these vital organs.
14 Both drugs are highly protein bound and eliminated primarily by the liver. 15 Both drugs are equally effective in closing the PDA in preterm infants. 7 Differences exist in the effect on cerebral and renal blood flow when using these two drugs. Indomethacin decreases cerebral blood flow and oxygen consumption to a greater degree than ibuprofen lysine. 16, 17 This is associated with a preventative effect in the occurrence of IVH when given prophylactically in low-birthweight infants, whereas ibuprofen lysine has no such protective effect. 18, 19 Indomethacin more profoundly decreases renal blood flow compared to ibuprofen lysine, resulting in significant oliguria and an increase in serum creatinine levels. 20, 21 Meta-analysis of studies comparing these drugs reveals no significant differences in the incidence of NEC, BPD at 36 weeks or neurodevelopmental outcome at 18 months of age. [22] [23] [24] Because these drugs are highly protein bound they can potentially compete with bilirubin for albumin binding sites and increase the risk of bilirubin encephalopathy. Studies have shown that at the recommended therapeutic dose of ibuprofen, the serum drug levels achieved do not increase free bilirubin levels. 25, 26 A few incidents of persistent pulmonary hypertension have been reported with ibuprofen than preparation 27 but this has not been seen with ibuprofen lysine, which is the only form of ibuprofen approved by the FDA in the United States.
Clinical studies of COX inhibitors to treat PDA Several clinical studies comparing indomethacin to placebo showed significant PDA closure rates 22, 23 and protective effects on IVH status when given as a prophylaxis for presymptomatic and symptomatic PDA. 18, 19 Schmidt et al. 28 (trial of indomethacin prophylaxis in preterms trial) looked at the neurodeveplomental outcome at 18 months of age when indomethacin was given as a prophylaxis compared to placebo. This study showed no differences in neurodevelopmetal outcome between both groups. Since the publication of this trial there was a reduction in prophylactic use of indomethacin to prevent IVH. 29 Ibuprofen lysine when given as prophylaxis compared to placebo showed significant PDA closure rates 22,23 but did not have an effect on the incidence of IVH. 30 Studies comparing indomethacin and ibuprofen lysine showed equal efficacy rates in ductal closure. 7, 31 In these comparative trials, the indomethacin group had statistically significant higher incidence of oliguria and elevated creatinine levels. There were no differences in the incidence of NEC, BPD or short-term neurological outcomes in patients receiving either of these COX inhibitors. [22] [23] [24] Meta-analysis of several comparison studies has reconfirmed these observations. 31 Recent analysis of children at 4 ½ and 8 years of age who were treated with indomethacin prophylaxis at birth showed favorable neurodevelopmental outcome vs those treated with placebo. 32, 33 Long-term neurological outcome in infants who received ibuprofen lysine is not yet available since it has only been approved for use since 2006.
Timing of treatment and drug of choice
The optimal time to treat the PDA is when treatment with COX inhibitors will be most effective while avoiding treatment of infants who may have spontaneous closure of the ductus. Therefore, prophylaxis treatment is only indicated in situations where the risk of IVH is very high. If prophylaxis is desired, indomethacin is the treatment of choice, as ibuprofen lysine has not been shown to have an effect on IVH. 34 The current trend is to treat early presymptomatic therapeutic PDA at 2 to 7 days of age after echocardiogram confirmation. This will minimize the number of babies exposed to COX inhibitors whose ductus will close spontaneously and at the same time benefit those babies who will respond most favorably to COX inhibitors. 35 Indomethacin and ibuprofen lysine have been shown to be equally effective in closure rates when given at this time. However, ibuprofen lysine will be preferable because of its better toxicity profile. 10, 35 Medical therapy should still be attempted for PDA closure beyond 7 days of age with the knowledge that treatment may be ineffective, as nonprostaglandin mechanisms are involved in keeping ductal patency by this age. Surgical ligation should be reserved for resistant symptomatic PDA that did not respond to medical and pharmacologic therapy. Table 1 
